What do systematic reviews say?

Leuprorelin vs treosulfan

It is very uncertain whether leuprorelin changes overall survival compared with treosulfan (very low certainty).

• Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer 2016 · Cochrane Headline outcomes only
  HR 0.98 [0.58, 1.67]
  Studies not reported
  Very low